Previous data on the clinical relevance of sPD-1 in ICI-treated NSCLC are much more limited (as compared to PD-L1) but seem to largely concur that higher posttreatment sPD-1 levels may represent a marker of improved survival. This evidence concerns the gene CD274 and non-small cell lung carcinoma.